Autophagy can regulate the occurrence and development of prostate cancer. In recent years, research on autophagy in prostate cancer has received widespread attention. However, there has been no bibliometric analysis in this field. Inorder to study the research status and hotspot of autophagy in prostate cancer in recent 20 years. We searched the literature on prostate cancer in the field of autophagy published in the Web of Science Core Database (WoSCC) between January 1, 2003 and April 1, 2023. We used CiteSpace 6.1R software to draw visual knowledge maps such as document publication trend chart, authors, research institutions, national and regional cooperation networks and keywords, and conduct bibliometric analysis. Resultly, a total of 770 papers were included, and the overall number of published papers showed an increasing trend. A total of 291 authors were included in the author collaboration Atlas, including 167 core authors. There are 231 institutions included in the Institutional Collaboration Map, of which only the University of California System has a centrality greater than 0.1. The authors are distributed in 58 countries, of which the largest number of articles published by PEOPLES R CHINA is 282. A total of 238 keywords were included, forming 12 clusters, 30 of which had a keyword frequency ≥30 times. Thus, the molecular mechanism of autophagy regulating the proliferation, apoptosis and metastasis of prostate cancer is a hot topic in current research. Drug resistance therapy of prostate cancer and development of new drugs targeting autophagy are the research trends.

Kang Cai, Yong Ou, Xiaoyong Gong. A bibliometric analysis of autophagy in prostate cancer from 2003 to 2023. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 8: 49-57. https://doi.org/10.25236/AJMHS.2023.040809.

[1] Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249. 

[2] Desai K, Mcmanus J M, Sharifi N. Hormonal Therapy for Prostate Cancer [J]. Endocr Rev, 2021, 42(3): 354-373. 

[3] Levine B, Kroemer G. Biological functions of autophagy genes: a disease perspective [J]. Cell, 2019, 176(1): 11-42. 

[4] Ashrafizadeh M, Paskeh M D A, Mirzaei S, et al. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response[J]. Journal of Experimental & Clinical Cancer Research, 2022, 41(1):1-37. 

[5] Ma C, Su H, Li H. Global research trends on prostate diseases and erectile dysfunction: a bibliometric and visualized study [J]. Frontiers in oncology, 2021, 10:627891. 

[6] Chen C. Science mapping: a systematic review of the literature [J]. Journal of data and information science, 2017, 2(2):1-40. 

[7] Luo H, Cai Z, Huang Y, et al. Study on pain catastrophizing from 2010 to 2020: a bibliometric analysis via CiteSpace [J]. Frontiers in Psychology, 2021, 12:759347. 

[8] Dang Q, Luo Z, Ouyang C, et al. First systematic review on health communication using the CiteSpace software in China: Exploring its research hotspots and frontiers [J]. International Journal of Environmental Research and Public Health, 2021, 18(24):13008. 

[9] Ma L, Ma J, Teng M, et al. Visual analysis of colorectal cancer immunotherapy: a bibliometric analysis from 2012 to 2021[J]. Frontiers in immunology, 2022, 13:843106. 

[10] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: a cancer journal for clinicians, 2021, 71(3):209-249. 

[11] Colhado Rodrigues B L, Lallo M A, Perez E C. The controversial role of autophagy in tumor development: A systematic review [J]. Immunological investigations, 2020, 49(4):386-396. 

[12] Jiang X, Zhong W, Huang H, et al. Autophagy defects suggested by low levels of autophagy activator MAP1S and high levels of autophagy inhibitor LRPPRC predict poor prognosis of prostate cancer patients [J]. Molecular carcinogenesis, 2015, 54(10):1194-1204. 

[13] Lin C, Blessing A M, Pulliam T L, et al. Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling [J]. Oncogene, 2021, 40(9):1690-1705. 

[14] Dai H, Hu W, Zhang L, et al. FGF21 facilitates autophagy in prostate cancer cells by inhibiting the PI3K–Akt–mTOR signaling pathway[J]. Cell Death & Disease, 2021, 12(4):303. 

[15] Chang H, Zou Z. Targeting autophagy to overcome drug resistance: further developments[J]. Journal of hematology & oncology, 2020, 13(1):1-18. 

[16] Siegel R L, Miller K D, Fedewa S A, et al. Colorectal cancer statistics, 2017[J]. CA: a cancer journal for clinicians, 2017, 67(3):177-193. 

[17] Nader R, El Amm J, Aragon-Ching J B. Role of chemotherapy in prostate cancer [J]. Asian journal of andrology, 2018, 20(3):221. 

[18] Mccubrey J A, Steelman L S, Abrams S L, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance[J]. Advances in enzyme regulation, 2006, 46(1): 249-279. 

[19] Chhipa R R, Wu Y, Ip C. AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia [J]. Cellular signalling, 2011, 23(9):1466-1472. 

[20] Gao S, Zhao Z, Wu R, et al. MiR-146b inhibits autophagy in prostate cancer by targeting the PTEN/Akt/mTOR signaling pathway [J]. Aging (Albany NY), 2018, 10(8):2113. 

[21] Wang Q, He W, Zeng Y, et al. Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells [J]. International Urology and Nephrology, 2018, 50:675-686. 

[22] Iwamoto H, Izumi K, Shimada T, et al. Androgen receptor signaling‐targeted therapy and taxane chemotherapy induce visceral metastasis in castration‐resistant prostate cancer[J]. The Prostate, 2021, 81(1): 72-80. 

[23] Mateo J, Seed G, Bertan C, et al. Genomics of lethal prostate cancer at diagnosis and castration resistance[J]. The Journal of clinical investigation, 2020, 130(4):1743-1751. 

[24] Nguyen H G, Yang J C, Kung H J, et al. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model [J]. Oncogene, 2014, 33(36):4521-4530. 

[25] Ramirez J A Z, Romagnoli G G, Kaneno R. Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy[J]. Life Sciences, 2021, 265:118745. 

[26] Ashrafizadeh M, Paskeh M D A, Mirzaei S, et al. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response[J]. Journal of Experimental & Clinical Cancer Research, 2022, 41(1):1-37.